Compare Archer Aviation Inc (ACHR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer Aviation Inc vs Recursion Pharmaceuticals Inc — how do they compare? Archer Aviation Inc trades at $6.3 (market cap $5.23B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Archer Aviation Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| ACHR | RXRX | |
|---|---|---|
Market Cap | $5.23B | $1.81B |
Sector | Industrials | Health |
52-Week High | $13.64 | $6.79 |
52-Week Low | $4.44 | $2.84 |
Enterprise Value | $3.79B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.41, up 2.4% today, with a bullish technical signal from moving averages. The stock shows strong analyst support (78% buy ratings) amid recent news of a strategic Boeing deal to acquire three businesses, boosting its defense and AI aviation portfolio. However, fundamentals remain weak with a P/S ratio of 719.85 and deeply negative profit margins, as the company is pre-revenue and burning cash to develop its eVTOL technology.
Outlook hinges on successful commercialization of air taxis and integration of Boeing assets, offering growth potential but carrying high execution risk. Investors face substantial losses until revenue scales, with net income margin at -11,590% in 2026. The Boeing partnership provides a cash flow bridge via defense revenue, yet dilution from equity offerings and regulatory delays pose near-term headwinds.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
